Labelling Review row-Online

Bond
EBER Probe
5.5 mL PB0589 P
For In Vitro Diagnostic Use
Components
Ready-to-use fluorescein-conjugated oligonucleotide probe directed to
Epstein-Barr Virus encoded RNA (EBER) transcripts in formalin-fixed,
paraffin-embedded tissue. Optimized for use with Bond Polymer Refine
Detection (DS9800) and Anti-Fluorescein Antibody (AR0833/AR0222).
Application
Epstein-Barr Virus (EBV) is a member of the Gamma Herpes Virus family. EBV
can establish both lytic infection as well as latent infection. Epstein Barr Virus
encoded RNA is abundantly expressed in latent EBV infection and ISH is
considered a sensitive method for the detection of latent EBV infection. Latent
EBV infection is associated with several conditions including: Hodgkin's
Lymphoma, B cell Non Hodgkin's Lymphoma, nasopharyngeal carcinoma,
lymphoproliferative disorders and lymphoma in the immunosuppressed,
including transplant and AIDS patients, gastric cancer and some T cell
lymphomas.
Hodgkin's lymphoma: in situ hybridization for Epstein-Barr virus (EBV) encoded mRNA using
EBV Probe, Anti-Flourescein Antibody and Bond Polymer Refine Detection.
HPV (subtypes 6, 11) Probe
6.25 mL ready-to-use PB0780 P
For In Vitro Diagnostic Use
Components
HPV (6,11) is a ready-to-use biotin-conjugated DNA probe directed to HPV
subtypes 6 and 11, for use in formalin-fixed paraffin embedded tissue. It has
been optimized for use with Bond Polymer Refine Detection (DS9800), Anti-
Biotin Antibody (AR0584) and Stringency Wash (AR0633).
Application
HPV infections have been associated with a number of malignant and
benign lesions, including genital warts, anogenital cancers and oral head
and neck cancers. Most notable HPV subtypes have been associated with
above 95 percent of cervical cancers. As a result, HPV subtypes are broadly
classified as high or low risk, depending on the incidence they are
associated with cervical malignant transformation (high risk) and benign
lesion development (low risk). There are 12 HPV subtypes classified as low
risk, including 6 and 11, which have a low association will cervical cancer
progression.
/46
For detailed information on all products please visit our website:
www.leica-microsystems.com
Cervical tissue (CIN1): in situ hybridization for HPV, subtype 6 and 11 DNA using HPV (6,11)
Probe, Anti-Biotin Antibody, Stringency Wash and Bond Polymer Refine Detection.
HPV (subtypes 16, 18, 31, 33, 51) Probe
6.25 mL ready-to-use PB0829 P
For In Vitro Diagnostic Use
Components
HPV (16, 18, 31, 33, 51) is a ready-to-use biotin-conjugated DNA probe
directed to HPV subtypes 16, 18, 31, 33 and 51, for use in formalin-fixed
paraffin-embedded tissue. It has been optimized for use with Bond Polymer
Refine Detection (DS9800), Anti-Biotin Antibody (AR0584) and Stringency
Wash (AR0633).
Application
HPV infections have been associated with a number of malignant and
benign lesions, including genital warts, anogenital cancers and oral head
and neck cancers. Most notable HPV subtypes have been associated with
above 95 percent of cervical cancer. As a result, HPV subtypes are broadly
classified as high or low risk, depending on the incidence they are
associated with cervical malignant transformation (high risk) and benign
lesion development (low risk).There are 15 HPV subtypes classified as high
risk, including 16, 18, 31, 33 and 51. HPV subtypes 16 and 18 are the most
frequent subtypes associated with cervical carcinogenesis and are
detected in up to 71 percent of cervical cancers.
Cervical tissue, abnormal epithelia (CINII) stained with HPV (subtypes 16, 18, 31,33, 51) Probe
Anti-Biotin Antibody, Stringency Wash and Bond Polymer Refine Detection.
Products in this catalog are subject to regulatory approval.
This catalog is not for use in the USA.